{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:56:21Z","timestamp":1790420181944,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.msard.2018.07.001","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T05:17:37Z","timestamp":1532063857000},"page":"95-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2679-4262","authenticated-orcid":false,"given":"Pedro","family":"S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Meca-Lallana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.07.001_bib0026","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.msard.2017.04.003","article-title":"Tumefactive demyelinating lesions: a comprehensive review","volume":"14","author":"Algahtani","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2018.07.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-206314","article-title":"Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?","author":"Alroughani","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.msard.2018.07.001_bib0002","first-page":"261","article-title":"Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations","volume":"12","author":"Ayzenberg","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"issue":"10","key":"10.1016\/j.msard.2018.07.001_bib0023","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1212\/WNL.0000000000003694","article-title":"Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab","volume":"88","author":"Barton","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.07.001_bib0008","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2015.03.022","article-title":"Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation","volume":"282","author":"Berger","year":"2015","journal-title":"J. Neuroimmunol"},{"issue":"5","key":"10.1016\/j.msard.2018.07.001_bib0017","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1468-1331.2011.03577.x","article-title":"Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study","volume":"19","author":"Borriello","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2018.07.001_bib0014","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbi.2015.06.019","article-title":"Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound","volume":"50","author":"Cavone","year":"2015","journal-title":"Brain Behav. Immun."},{"issue":"18","key":"10.1016\/j.msard.2018.07.001_bib0022","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/WNL.0000000000002084","article-title":"Extensive brain demyelinating lesions under natalizumab: the role of anti-natalizumab antibodies","volume":"85","author":"Debs","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2018.07.001_bib0013","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1756285615594575","article-title":"Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment","volume":"8","author":"Faissner","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2018.07.001_bib0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00415-012-6744-7","article-title":"Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients","volume":"260","author":"Ghezzi","year":"2013","journal-title":"J. Neurol. Ger."},{"issue":"9","key":"10.1016\/j.msard.2018.07.001_bib0010","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/jnnp-2012-304498","article-title":"Tumefactive demyelination: an approach to diagnosis and management","volume":"84","author":"Hardy","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.msard.2018.07.001_bib0019","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.msard.2015.05.007","article-title":"Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: a case report","volume":"4","author":"Harirchian","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2018.07.001_bib0007","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2018.07.001_bib0006","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archneurol.2011.1057","article-title":"Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment","volume":"69","author":"Havla","year":"2012","journal-title":"Arch. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2018.07.001_bib0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jns.2014.06.013","article-title":"Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy","volume":"344","author":"Hellmann","year":"2014","journal-title":"J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.msard.2018.07.001_bib0020","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1177\/1352458512463768","article-title":"Hartung H-P. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod","volume":"18","author":"Jander","year":"2012","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2018.07.001_bib0001","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.msard.2018.07.001_bib0016","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s00415-011-6019-8","article-title":"Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study","volume":"258","author":"Magraner","year":"2011","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2018.07.001_bib0011","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1212\/WNL.54.7.1427","article-title":"Open-ring imaging sign: highly specific for atypical brain demyelination","volume":"54","author":"Masdeu","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2018.07.001_bib0024","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult. Scler."},{"issue":"22","key":"10.1016\/j.msard.2018.07.001_bib0004","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O'Connor","year":"2011","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.msard.2018.07.001_bib0027","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000435293.34351.11","article-title":"Tumefactive MS lesions under fingolimod: a case report and literature review","volume":"81","author":"Pilz","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.07.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215596","article-title":"Severe tumefactive rebound of multiple sclerosis following fingolimod cessation","author":"Salam","year":"2016","journal-title":"BMJ Case Rep."},{"issue":"6","key":"10.1016\/j.msard.2018.07.001_bib0003","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2018.07.001_bib0021","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jns.2010.01.001","article-title":"A giant MS plaque mimicking PML during natalizumab treatment","volume":"291","author":"Twyman","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"19","key":"10.1016\/j.msard.2018.07.001_bib0018","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1212\/WNL.0b013e3182735cb3","article-title":"Tumefactive multiple sclerosis lesions under fingolimod treatment","volume":"79","author":"Visser","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2018.07.001_bib0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.07.001_bib0028","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.msard.2017.10.006","article-title":"A possible role of impaired cell-mediated immunity in the pathogenesis of tumefactive demyelinating lesions","volume":"18","author":"Koudriavtseva","year":"2017","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:45:31Z","timestamp":1761900331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818301998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":28,"alternative-id":["S2211034818301998"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.07.001","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}